Vivimed Labs Enters Insolvency Proceedings

Vivimed Labs Limited has entered formal insolvency proceedings after an order from the National Company Law Tribunal (NCLT), Bengaluru Bench, effective April 15, 2026. This action was prompted by a petition from German creditor Blue Cube Germany Assets GmbH & Co. KG over an unpaid operational debt of ₹2,78,60,844, concerning perchloroethylene supplied between 2012 and 2014.

Insolvency Management and Deadlines

An Interim Resolution Professional (IRP), T Narayana Swamy, has been appointed to oversee the company's affairs. Creditors must submit their claims with proof by May 1, 2026. The insolvency resolution process is expected to conclude by October 11, 2026, depending on the progress of the restructuring.

Background of Financial Distress

Vivimed Labs has faced prolonged financial challenges. The company defaulted on loan repayments, leading State Bank of India (SBI) to classify its account as a non-performing asset (NPA) and initiate a forensic audit in March 2022. Its financial assets were later acquired by Rare Asset Reconstruction Ltd. (Rare ARC) from SBI around October 2025. A Central Bureau of Investigation (CBI) probe into alleged financial irregularities was also underway, following an SBI complaint classifying the account as 'fraud'.

Scale of Debt and Previous Filings

Before this NCLT order, Vivimed Labs had applied for a pre-pack insolvency resolution process (PPIRP) in February 2026, reporting a default amount of ₹512.53 Crores as of January 31, 2026. The NCLT noted multiple other insolvency petitions were pending against the company.

Process and Legal Ramifications

The company's future is now subject to restructuring under India's insolvency law. A legal moratorium is in effect, halting lawsuits and asset transfers against Vivimed Labs. The Interim Resolution Professional (IRP) manages operations, and creditors will form a Committee of Creditors (CoC) to evaluate the company's status and decide on a resolution plan.

Impact on Shareholders and Risks

Shareholders face a high risk of significant dilution or loss of investment, as creditors have priority in recovery. The company's survival depends on an agreed resolution plan; failure could lead to liquidation, causing substantial losses for all stakeholders. The ongoing CBI investigation adds further complexity and risk to the process.

Industry Context

Vivimed Labs operates in the pharmaceutical and specialty chemicals sectors. While major players like Divi's Laboratories, Laurus Labs, and Aarti Industries exist in similar segments, direct peer comparison is difficult due to Vivimed's advanced stage of insolvency proceedings.

Key Dates and Next Steps

Important dates to monitor include the May 1, 2026, creditor claim deadline and the estimated October 11, 2026, process closure. Investors will track claim submissions, Committee of Creditors decisions, and resolution plan progress. The IRP's report is due for review at the June 24, 2026, hearing.